ATLAS / Macro Radar / Reporting / ABCL

AbCellera Biologics Inc. (ABCL) reporting calendar

AbCellera Biologics Inc. files periodic reports with the SEC as ABCL on Nasdaq. Atlas tracks 22 filed reports for this issuer, each linked to its original EDGAR accession.

Next window
27 Jul 2026 – 18 Aug 2026
Latest report
10-Q
Period ended
31 Mar 2026
Filed
11 May 2026
Reports on record
22

How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 38 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.

Filed periodic reports

FormPeriod endedFiledLagSEC accession
10-Q31 Mar 202611 May 202641 days0001703057-26-000028
10-K31 Dec 202524 Feb 202655 days0001703057-26-000012
10-Q30 Sep 20256 Nov 202537 days0001703057-25-000025
10-Q30 Jun 20257 Aug 202538 days0001703057-25-000011
10-Q31 Mar 20258 May 202538 days0001628280-25-023836
10-K31 Dec 202427 Feb 202558 days0001628280-25-008689
10-Q30 Sep 20244 Nov 202435 days0001628280-24-045026
10-Q30 Jun 20246 Aug 202437 days0001628280-24-035248
10-Q31 Mar 20247 May 202437 days0001628280-24-021159
10-K31 Dec 202320 Feb 202451 days0001703057-24-000019
10-Q30 Sep 20232 Nov 202333 days0001703057-23-000040
10-Q30 Jun 20233 Aug 202334 days0001703057-23-000022
10-Q31 Mar 20234 May 202334 days0001703057-23-000008
10-K31 Dec 202221 Feb 202352 days0001564590-23-002128
10-Q30 Sep 20228 Nov 202239 days0001564590-22-037060
10-Q30 Jun 20229 Aug 202240 days0001564590-22-028784
10-Q31 Mar 202210 May 202240 days0001564590-22-019294
10-K31 Dec 202125 Feb 202256 days0001564590-22-007077
10-Q30 Sep 202110 Nov 202141 days0001564590-21-056205
10-Q30 Jun 202113 Aug 202144 days0001564590-21-044327
10-Q31 Mar 202114 May 202144 days0001564590-21-028008
10-K31 Dec 202030 Mar 202189 days0001564590-21-016713

Source: SEC EDGAR company submissions for CIK 0001703057. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.